Abstract:ABSTRACT Two Baeyer-Villiger monooxygenases (BVMOs), designated Bo BVMO and Am BVMO, were discovered from Bradyrhizobium oligotrophicum and Aeromicrobium marinum , respectively. Both monooxygenases displayed novel features for catalyzing the asymmetric sulfoxidation of bulky and pharmaceutically relevant thioethers. Evolutionary relationship and sequence analysis revealed that the two BVMOs belong to the family of typical type I BVMOs and the subtype ethionamide monooxygenase. Both BVMOs are active toward medium- and long-chain aliphatic ketones as well as various thioether substrates but are ineffective toward cyclohexanone, aromatic ketones, and other typical BVMO substrates. Bo BVMO and Am BVMO showed the highest activities (0.117 and 0.025 U/mg protein, respectively) toward thioanisole among the tested substrates. Furthermore, these BVMOs exhibited distinct activity and excellent stereoselectivity toward bulky and prochiral prazole thioethers, which is a unique feature of this family of BVMOs. No native enzyme has been reported for the asymmetric sulfoxidation of bulky prazole thioethers into chiral sulfoxides. The identification of Bo BVMO and Am BVMO provides an important scaffold for discovering enzymes capable of asymmetrically oxidizing bulky thioether substrates by genome mining. IMPORTANCE Baeyer-Villiger monooxygenases (BVMOs) are valuable enzyme catalysts that are an alternative to the chemical Baeyer-Villiger oxidation reaction. Although BVMOs display broad substrate ranges, no native enzymes were reported to have activity toward the asymmetric oxidation of bulky prazole-like thioether substrates. Herein, we report the discovery of two type I BVMOs from Bradyrhizobium oligotrophicum ( Bo BVMO) and Aeromicrobium marinum ( Am BVMO) which are able to catalyze the asymmetric sulfoxidation of bulky prazole thioethers (proton pump inhibitors [PPIs], a group of drugs whose main action is a pronounced and long-lasting reduction of gastric acid production). Efficient catalysis of omeprazole oxidation by Bo BVMO was developed, indicating that this enzyme is a promising biocatalyst for the synthesis of bulky and pharmaceutically relevant chiral sulfoxide drugs. These results demonstrate that the newly identified enzymes are suitable templates for the discovery of more and better thioether-converting BVMOs.

Colorimetric high‐throughput screening method for directed evolution of prazole sulfide monooxygenase

Enzymatic synthesis of pharmacologically relevant chiral sulfoxides by improved CbBVMO variants

A Baeyer-Villiger monooxygenase from Cupriavidus basilensis catalyzes asymmetric synthesis of (R)-lansoprazole and other pharmaco-sulfoxides

Precise regulation of the substrate selectivity of Baeyer-Villiger monooxygenase to minimize overoxidation of prazole sulfoxides

Discovery of Two Native Baeyer-Villiger Monooxygenases for Asymmetric Synthesis of Bulky Chiral Sulfoxides.

Rational design on loop regions for precisely regulating flexibility of catalytic center to mitigate overoxidation of prazole sulfides by Baeyer-Villiger monooxygenase

Protein engineering of thioether monooxygenase to improve its thermostability for enzymatic synthesis of chiral sulfoxide

Recreating the natural evolutionary trend in key microdomains provides an effective strategy for engineering of a thermomicrobial <i>N</i>-demethylase

Directed evolution of Baeyer–Villiger monooxygenase for highly secretory expressed in Pichia pastoris and efficient preparation of chiral pyrazole sulfoxide

Compensation of the Enantioselectivity-Activity Trade-off in the Directed Evolution of an Esterase from Rhodobacter Sphaeroides by Site-Directed Saturation Mutagenesis

Recent Developments in Protein Engineering and Catalytic Oxidations of Baeyer-Villiger Monooxygenase

Enzymatic Preparation Of The Chiral (S)-Sulfoxide Drug Esomeprazole At Pilot-Scale Levels

Identification two key residues at the intersection of domains of a thioether monooxygenase for improving its sulfoxidation performance

Engineering of Cyclohexanone Monooxygenase for the Enantioselective Synthesis of (S)-Omeprazole

Expanding the toolbox of Baeyer-Villiger and flavin monooxygenase biocatalysts for the enantiodivergent green synthesis of sulfoxides

Customizing the Enantioselectivity of a Cyclohexanone Monooxygenase by a Strategy Combining “size‐probes” with in Silico Study

Towards practical Baeyer-Villiger-monooxygenases: design of cyclohexanone monooxygenase mutants with enhanced oxidative stability

Engineering of a Baeyer‐Villiger monooxygenase to improve substrate scope, stereoselectivity and regioselectivity

Through virtual saturation mutagenesis and rational design for superior substrate conversion in engineered d‐amino acid oxidase

Recent developments in the application of Baeyer-Villiger monooxygenases as biocatalysts

Discovery and Engineering of a Novel Baeyer‐Villiger Monooxygenase with High Normal Regioselectivity